Xinhua News Agency, May 8, * ST Zixin announcement, Guoyao Zhaoxiang (Changchun) Pharmaceutical Co., Ltd., the company's controlling shareholder, recently received a "notice of filing a case" issued by the Securities Regulatory Commission. The CSRC decided to file a case against Guoyao Zhaoxiang (Changchun) Pharmaceutical Co., Ltd. on suspicion of trading Zixin Pharmaceutical shares during the restricted period. In addition, after the audit of the annual report in 2022, the net profit of the company before and after deducting non-recurring profits and losses in the last three fiscal years is negative, and the audit report of the most recent year shows that there is uncertainty about the company's sustainable operating ability. The Shenzhen Stock Exchange has implemented superimposed other risk warnings on the company's stock trading since May 9.